TRIB3 and Retinal dystrophy: To our knowledge, this is the first study that has validated TRB3 as a therapeutic target in animal models of retinal degeneration; this study emphasizes the critical need to generate a TRB3-based cellular therapy to retard inherited retinal dystrophies.